Evidence map›Paper›PMID 36010837›Full record

ArticleCancers2022

High Expression of CUL9 Is Prognostic and Predictive for Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer.

Peng Zheng, Yang Lv, Yihao Mao, Feifan Shen, Zhiyuan Zhang, Jiang Chang, Shanchao Yu, Meiling Ji, Qingyang Feng, Jianmin Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Peng ZhengGeneral Surgery Department, Zhongshan Hospital, Fudan University, 180 Fenglin Rd., Shanghai 200032, China.
Yang LvGeneral Surgery Department, Zhongshan Hospital, Fudan University, 180 Fenglin Rd., Shanghai 200032, China.
Yihao MaoGeneral Surgery Department, Zhongshan Hospital, Fudan University, 180 Fenglin Rd., Shanghai 200032, China.
Feifan ShenShanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai 200032, China.
Zhiyuan ZhangGeneral Surgery Department, Zhongshan Hospital, Fudan University, 180 Fenglin Rd., Shanghai 200032, China.
Jiang ChangGeneral Surgery Department, Zhongshan Hospital, Fudan University, 180 Fenglin Rd., Shanghai 200032, China.
Shanchao YuShanghai Engineering Research Center of Colorectal Cancer Minimally Invasive, Shanghai 200032, China.
Meiling JiGeneral Surgery Department, Zhongshan Hospital, Fudan University, 180 Fenglin Rd., Shanghai 200032, China.
Qingyang FengGeneral Surgery Department, Zhongshan Hospital, Fudan University, 180 Fenglin Rd., Shanghai 200032, China.
Jianmin XuGeneral Surgery Department, Zhongshan Hospital, Fudan University, 180 Fenglin Rd., Shanghai 200032, China.
Shanghai Cancer Institute · CNFudan University · CNShanghai Medical College of Fudan University · CN

Funding

National Natural Science Foundation of China 81903067
6 · The paper itself

Abstract

We evaluated the clinical implications of CUL9 expression on the prognosis and the predictive value for adjuvant chemotherapy in colon cancer. A total of 1078 consecutive patients treated with radical resection from 2008 to 2012 were included. Formalin-fixed, paraffin-embedded specimens were used as immunohistochemistry (IHC) for CUL9. For all patients, high expression of CUL9 was identified as an independent prognostic factor for overall survival (HR = 1.613, 95% CI 1.305−1.993, p < 0.001) and disease-free survival (HR = 1.570, 95% CI 1.159−2.128, p = 0.004). The prognostic value of high CUL9 expression was confirmed in an independent validation cohort from the GEO database. The efficacy of adjuvant chemotherapy was analyzed among patients with high-risk stage II and stage III disease. Those with high CUL9 expression from the full dose group had better disease-free survival (HR = 0.477, 95% CI 0.276−0.825, p = 0.006) than those from the reduced dose group. The interaction test between CUL9 expression and the treatment reached significance and was not confounded by T stage, N stage and histopathological grade. In general, high expression of CUL9 was an independent prognostic factor in patients with colon cancer. In those with high-risk stage II and stage III disease, high expression of CUL9 was associated with the benefit from standard 6-months adjuvant chemotherapy regimens.

Indexed as

adjuvant chemotherapycolorectal cancerCUL9immunohistochemistry

Identifiers

PMID36010837
PMCPMC9406063
OpenAlexW4293514528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.